Abstract
In this report we show that submicromolar concentrations of dexamethasone enhance pregnane X receptor (PXR) activator-mediated CYP3A4 gene expression in cultured human hepatocytes. Because this result is only observed after 24 h of cotreatment and is inhibited by pretreatment with cycloheximide, we further investigated which factor(s), induced by dexamethasone, might be responsible for this effect. We report that dexamethasone increases both retinoid X receptor-α (RXRα) and PXR mRNA expression in cultured human hepatocytes, whereas PXR activators such as rifampicin and clotrimazole do not. Accumulation of RXRα and PXR mRNA reaches a maximum at a concentration of 100 nM dexamethasone after treatment for 6 to 12 h and is greatly diminished by RU486. A similar pattern of expression is observed with tyrosine aminotransferase mRNA. Moreover, the effect of dexamethasone on PXR mRNA accumulation seems to be through direct action on the glucocorticoid receptor (GR) because the addition of cycloheximide has no effect, and dexamethasone does not affect the degradation of PXR mRNA. Furthermore, dexamethasone induces the accumulation of a RXRα-immunoreactive protein and increases the nuclear level of RXRα:PXR heterodimer as shown by gel shift assays with a CYP3A4 ER6 PXRE probe. This accumulation of latent PXR and RXRα in the nucleus of hepatocytes explains the synergistic effect observed with dexamethasone and PXR activators together on CYP3A4 induction. These results reveal the existence of functional cross talk between the GR and PXR, and may explain some controversial aspects of the role of the GR in CYP3A4 induction.
Footnotes
- Received November 30, 1999.
- Accepted May 17, 2000.
-
Send reprint requests to: Marie-José Vilarem, Institut National de la Santé et de la Recherche Médicale U128, 1919 Route de Mende, 34293 Montpellier Cedex 05, France. E-mail:vilarem{at}crbm.cnrs-mop.fr
-
↵1 Current address: Service de Chirurgie, Hopital Saint Eloi, 34295 Montepellier Cedex 05 France.
-
This study was supported by grants from the Institut National de la Santé et de la Recherche Médicale, the Ligue Nationale contre le Cancer (to J.M.P.) and Glaxo Wellcome (to L.D.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|